PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: bapineuzumab
Drug: placebo

First Posted Date: 2008-04-28

Last Posted Date: 2016-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 901

Registration Number: NCT00667810

Locations: 🇺🇸
Clinical Trials, Inc., Little Rock, Arkansas, United States
🇺🇸
Center for Healthy Aging, Greenwich, Connecticut, United States
🇺🇸
Chase Medical Research, LLC, Waterbury, Connecticut, United States

and more 328 locations

Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: Staphylococcal Infections

Interventions: Drug: linezolid (Zyvox)

First Posted Date: 2008-04-24

Last Posted Date: 2012-07-02

Lead Sponsor: Pfizer

Target Recruit Count: 1004

Registration Number: NCT00666276

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

Phase 2

Completed

Conditions: Dental Pain

Interventions: Drug: ARRY-371797, p38 inhibitor; oral
Drug: Celecoxib, COX-2 inhibitor; oral
Drug: Placebo; oral

First Posted Date: 2008-04-22

Last Posted Date: 2021-02-09

Lead Sponsor: Pfizer

Target Recruit Count: 250

Registration Number: NCT00663767

Locations: 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
🇺🇸
Lifetree Clinical Research, Salt Lake City, Utah, United States

Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: bapineuzumab
Drug: placebo

First Posted Date: 2008-04-21

Last Posted Date: 2013-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT00663026

Locations: 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States

Study Of Sunitinib With Capecitabine In Breast Cancer

Phase 2

Completed

Conditions: Advanced/Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Sunitinib

First Posted Date: 2008-04-21

Last Posted Date: 2013-05-27

Lead Sponsor: Pfizer

Target Recruit Count: 63

Registration Number: NCT00662025

Locations: 🇯🇵
Pfizer Investigational Site, Osaka, Japan

Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients

Phase 2

Completed

Conditions: Diabetic Foot Ulcer

Interventions: Drug: Placebo for Fragmin/ Dalteparin Sodium
Drug: Fragmin/ Dalteparin Sodium

First Posted Date: 2008-04-21

Last Posted Date: 2018-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 276

Registration Number: NCT00662831

Locations: 🇬🇧
Pfizer Investigational Site, Peterborough, United Kingdom

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

Phase 4

Completed

Conditions: Plaque Psoriasis
Psoriasis

Interventions: Drug: Etanercept

First Posted Date: 2008-04-21

Last Posted Date: 2012-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 273

Registration Number: NCT00663052

Locations: 🇹🇭
Pfizer Investigational Site, Bangkok, Thailand

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

Phase 1

Completed

Conditions: Smoking Cessation

Interventions: Drug: varenicline tartrate
Drug: varenicline free base

First Posted Date: 2008-04-18

Last Posted Date: 2009-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT00661765

Locations: 🇺🇸
Pfizer Investigational Site, Fargo, North Dakota, United States

Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: CP-690,550

First Posted Date: 2008-04-18

Last Posted Date: 2015-05-12

Lead Sponsor: Pfizer

Target Recruit Count: 487

Registration Number: NCT00661661

Locations: 🇯🇵
Chiba-ken Saiseikai Narashino Hospital, Narashino, Chiba, Japan
🇯🇵
National hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan

and more 53 locations

A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain

Phase 3

Completed

Conditions: Laparoscopic Cholecystectomy
Pain

Interventions: Drug: placebo
Drug: valdecoxib

First Posted Date: 2008-04-18

Last Posted Date: 2008-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 490

Registration Number: NCT00661635

Locations: 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy